Your browser doesn't support javascript.
loading
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Ma, Shuo; Seymour, John F; Brander, Danielle M; Kipps, Thomas J; Choi, Michael Y; Anderson, Mary Ann; Humphrey, Kathryn; Al Masud, Abdullah; Pesko, John; Nandam, Ruby; Salem, Ahmed Hamed; Chyla, Brenda; Arzt, Jennifer; Jacobson, Amanda; Kim, Su Young; Roberts, Andrew W.
Afiliación
  • Ma S; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Seymour JF; Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Brander DM; University of Melbourne, Parkville, VIC, Australia.
  • Kipps TJ; Duke University Medical Center, Durham, NC.
  • Choi MY; University of California San Diego, San Diego, CA.
  • Anderson MA; University of California San Diego, San Diego, CA.
  • Humphrey K; Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Al Masud A; University of Melbourne, Parkville, VIC, Australia.
  • Pesko J; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Nandam R; Roche, Basel, Switzerland.
  • Salem AH; AbbVie Inc, North Chicago, IL; and.
  • Chyla B; AbbVie Inc, North Chicago, IL; and.
  • Arzt J; AbbVie Inc, North Chicago, IL; and.
  • Jacobson A; AbbVie Inc, North Chicago, IL; and.
  • Kim SY; Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt.
  • Roberts AW; AbbVie Inc, North Chicago, IL; and.
Blood ; 138(10): 836-846, 2021 09 09.
Article en En | MEDLINE | ID: mdl-34115103
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (200-600 mg) and rituximab over 6 months and then received venetoclax monotherapy. Patients achieving complete response (CR), CR with incomplete marrow recovery (CRi), or undetectable minimal residual disease (uMRD) assessed by flow cytometry (<10-4 cutoff) were allowed, but not required, to discontinue therapy, while remaining in the study and could be retreated with VenR upon progression. Median follow-up for all patients (N = 49) was 5.3 years. Five-year rates (95% CI) for overall survival, progression-free survival, and duration of response were 86% (72-94), 56% (40-70), and 58% (40-73), respectively. Of the 33 deep responders (CR/CRi or uMRD), 14 remained on venetoclax monotherapy (continuous therapy), and 19 stopped venetoclax therapy (limited-duration therapy) after a median of 1.4 years. Five-year estimates of ongoing response were similar between continuous (71%; 95% CI, 39-88) or limited-duration therapy (79% [49-93]). Six of 19 patients in the latter group had subsequent disease progression, all >2 years off venetoclax (range, 2.1-6.4). Four patients were retreated with VenR, with partial responses observed in the 3 evaluable to date. VenR induced deep responses that were highly durable with either continuous or limited-duration therapy. Retreatment with VenR induced responses in patients with CLL progression after discontinuing therapy. Continuous exposure to venetoclax in deep responders does not appear to provide incremental benefit.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos